prochlorperazine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2274 58-38-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • prochlorperazine mesylate
  • prochlorperazine
  • capazine
  • chlormeprazine
  • chlorperazine
  • meterazin
  • meterazine
  • proazine
  • prochlorpemazine
  • prochlorperazin
  • prochlorpromazine
  • prochlorperazine maleate
  • prochlorperazine edisylate
  • prochlorperazine dimaleate
  • prochlorperzine
A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)
  • Molecular weight: 373.94
  • Formula: C20H24ClN3S
  • CLOGP: 4.58
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 0
  • TPSA: 9.72
  • ALOGS: -4.53
  • ROTB: 4

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 g O
50 mg P
0.10 g R

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.10 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.83 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 15 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 22 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 16 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 9 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Oct. 23, 1956 FDA GLAXOSMITHKLINE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 346.01 11.57 467 52489 97200 50454968
Drug ineffective 301.57 11.57 251 52705 819082 49733086
Disease progression 257.20 11.57 402 52554 95464 50456704
Dehydration 236.43 11.57 504 52452 151945 50400223
Diarrhoea 216.94 11.57 1196 51760 587280 49964888
Plasma cell myeloma 216.86 11.57 212 52744 31110 50521058
Nausea 213.56 11.57 1361 51595 704037 49848131
White blood cell count decreased 206.99 11.57 408 52548 116314 50435854
Vomiting 197.47 11.57 977 51979 459781 50092387
Platelet count decreased 147.95 11.57 326 52630 100400 50451768
Contraindicated product administered 141.25 11.57 3 52953 148955 50403213
Fatigue 140.09 11.57 1236 51720 706365 49845803
Death 125.72 11.57 671 52285 324708 50227460
Neutropenia 122.86 11.57 387 52569 147578 50404590
Synovitis 115.47 11.57 3 52953 123862 50428306
Systemic lupus erythematosus 113.19 11.57 9 52947 140613 50411555
Arthropathy 109.79 11.57 17 52939 157889 50394279
Constipation 108.78 11.57 433 52523 185275 50366893
Malignant neoplasm progression 99.41 11.57 220 52736 67904 50484264
Asthenia 95.93 11.57 616 52340 318426 50233742
Toxicity to various agents 95.08 11.57 52 52904 212447 50339721
Therapeutic product effect decreased 93.77 11.57 15 52941 136035 50416133
Joint swelling 90.96 11.57 74 52882 245212 50306956
Decreased appetite 81.98 11.57 421 52535 200502 50351666
Glossodynia 79.05 11.57 13 52943 115556 50436612
Blood magnesium decreased 76.20 11.57 75 52881 11085 50541083
Neutrophil count decreased 75.61 11.57 156 52800 45870 50506298
Abdominal pain 72.06 11.57 458 52498 235770 50316398
Full blood count decreased 71.68 11.57 102 52854 22244 50529924
Neovascularisation 71.35 11.57 30 52926 983 50551185
Neoplasm progression 69.50 11.57 116 52840 29041 50523127
Neuropathy peripheral 69.43 11.57 241 52715 96516 50455652
Hospice care 66.01 11.57 52 52904 5720 50546448
Thrombosis 65.88 11.57 166 52790 55667 50496501
Pericarditis 63.39 11.57 5 52951 78684 50473484
Pleural effusion 62.94 11.57 208 52748 81246 50470922
Heart rate abnormal 61.45 11.57 43 52913 3949 50548219
Therapeutic product effect incomplete 61.03 11.57 11 52945 91504 50460664
Condition aggravated 60.26 11.57 139 52817 296919 50255249
Akathisia 59.36 11.57 57 52899 8172 50543996
Carbohydrate antigen 125 increased 58.83 11.57 35 52921 2432 50549736
Rheumatoid arthritis 56.15 11.57 78 52878 202472 50349696
Lymphadenitis 53.88 11.57 34 52922 2626 50549542
Clostridium difficile infection 53.80 11.57 96 52860 25343 50526825
Gangrene 53.07 11.57 42 52914 4650 50547518
Completed suicide 51.10 11.57 38 52918 131851 50420317
Small intestinal obstruction 51.02 11.57 73 52883 15995 50536173
Arterial occlusive disease 50.06 11.57 41 52915 4767 50547401
Infusion related reaction 49.32 11.57 63 52893 169494 50382674
Thrombocytopenia 48.21 11.57 262 52694 127411 50424757
Red blood cell count decreased 47.90 11.57 108 52848 33727 50518441
Drug abuse 47.66 11.57 4 52952 59842 50492326
Drug intolerance 47.30 11.57 99 52857 219005 50333163
Swelling 46.60 11.57 87 52869 200785 50351383
Cytokine release syndrome 46.32 11.57 51 52905 8583 50543585
Maternal exposure during pregnancy 45.82 11.57 60 52896 159718 50392450
Injection site pain 45.63 11.57 30 52926 110994 50441174
Colitis 44.86 11.57 114 52842 38415 50513753
Pancytopenia 44.42 11.57 190 52766 83840 50468328
Lower respiratory tract infection 42.96 11.57 23 52933 95178 50456990
Wound 42.92 11.57 29 52927 105765 50446403
Coma 42.17 11.57 5 52951 56874 50495294
Hepatic enzyme increased 42.11 11.57 49 52907 137331 50414837
Injection site erythema 42.10 11.57 13 52943 74923 50477245
Pain 41.44 11.57 397 52559 578506 49973662
Pneumonitis 39.35 11.57 92 52864 29418 50522750
Palmar-plantar erythrodysaesthesia syndrome 38.90 11.57 73 52883 20025 50532143
Weight decreased 38.54 11.57 377 52579 220868 50331300
Failure to thrive 38.41 11.57 40 52916 6318 50545850
General physical health deterioration 38.31 11.57 56 52900 142378 50409790
Pneumonia 37.28 11.57 579 52377 377822 50174346
Treatment failure 36.16 11.57 55 52901 137582 50414586
Paradoxical drug reaction 35.68 11.57 30 52926 3617 50548551
Intentional overdose 34.83 11.57 11 52945 62493 50489675
Hair colour changes 34.33 11.57 26 52930 2698 50549470
Alopecia areata 34.17 11.57 20 52936 1348 50550820
Blood creatine increased 33.65 11.57 33 52923 4854 50547314
Hair texture abnormal 33.57 11.57 29 52927 3627 50548541
Injection site reaction 33.38 11.57 6 52950 50026 50502142
Haemoglobin decreased 32.35 11.57 236 52720 126980 50425188
Mobility decreased 32.31 11.57 22 52934 79926 50472242
Anaemia 31.98 11.57 404 52552 252052 50300116
Discomfort 31.78 11.57 40 52916 108340 50443828
Hypokalaemia 31.48 11.57 178 52778 87814 50464354
Blood potassium decreased 30.92 11.57 97 52859 36848 50515320
Rectal cancer metastatic 30.39 11.57 11 52945 239 50551929
Off label use 30.33 11.57 334 52622 474092 50078076
Hyponatraemia 30.22 11.57 188 52768 95951 50456217
Folliculitis 30.21 11.57 3 52953 39222 50512946
Back pain 29.97 11.57 357 52599 219673 50332495
Mucosal inflammation 29.65 11.57 101 52855 40041 50512127
Suicide attempt 29.01 11.57 9 52947 51723 50500445
Irritable bowel syndrome 28.75 11.57 9 52947 51432 50500736
Taste disorder 28.18 11.57 39 52917 8285 50543883
Hypophagia 28.17 11.57 78 52878 27650 50524518
Sepsis 27.95 11.57 236 52720 132689 50419479
Musculoskeletal stiffness 27.74 11.57 58 52898 128423 50423745
Drug hypersensitivity 26.97 11.57 390 52566 250620 50301548
Knee arthroplasty 26.94 11.57 3 52953 35843 50516325
Psoriatic arthropathy 26.70 11.57 8 52948 47024 50505144
Muscle twitching 26.15 11.57 53 52903 15378 50536790
Oral pain 26.01 11.57 71 52885 24962 50527206
Injection site swelling 25.81 11.57 6 52950 41767 50510401
Dysgeusia 25.38 11.57 94 52862 38822 50513346
Exposure during pregnancy 24.99 11.57 56 52900 120959 50431209
Weight increased 24.62 11.57 118 52838 201773 50350395
Red cell distribution width increased 24.45 11.57 37 52919 8522 50543646
Overdose 24.17 11.57 42 52914 99685 50452483
Pyrexia 23.31 11.57 541 52415 379662 50172506
Drug interaction 23.01 11.57 119 52837 199502 50352666
Deep vein thrombosis 22.81 11.57 143 52813 73161 50479007
Skin exfoliation 22.60 11.57 82 52874 33530 50518638
Gastric disorder 22.39 11.57 75 52881 29473 50522695
Arthralgia 22.35 11.57 324 52632 438378 50113790
Laboratory test abnormal 22.32 11.57 64 52892 23144 50529024
Hypersensitivity 22.22 11.57 133 52823 215028 50337140
Ill-defined disorder 22.13 11.57 15 52941 54639 50497529
Lymphadenopathy 21.92 11.57 81 52875 33418 50518750
Cholestasis of pregnancy 21.77 11.57 14 52942 1117 50551051
Hip arthroplasty 21.76 11.57 3 52953 30426 50521742
C-reactive protein increased 21.13 11.57 23 52933 66451 50485717
Red blood cell sedimentation rate increased 20.81 11.57 3 52953 29413 50522755
Autoimmune nephritis 20.74 11.57 9 52947 319 50551849
Hypoxia 20.70 11.57 107 52849 51016 50501152
Extrapyramidal disorder 20.63 11.57 41 52915 11729 50540439
Abdominal discomfort 20.49 11.57 150 52806 231491 50320677
Fibromyalgia 20.09 11.57 11 52945 44967 50507201
Dry skin 20.05 11.57 94 52862 43097 50509071
Pulmonary embolism 19.51 11.57 177 52779 101527 50450641
Tumour marker increased 19.43 11.57 22 52934 3818 50548350
Loss of personal independence in daily activities 19.36 11.57 27 52929 70023 50482145
Skull fracture 19.17 11.57 12 52944 914 50551254
Nasopharyngitis 19.01 11.57 121 52835 192806 50359362
Madarosis 18.97 11.57 18 52938 2542 50549626
Plasma cell myeloma recurrent 18.40 11.57 18 52938 2640 50549528
Breast cancer metastatic 18.04 11.57 36 52920 10328 50541840
Injection site bruising 17.92 11.57 8 52948 36760 50515408
Injection site pruritus 17.88 11.57 10 52946 40401 50511767
Product use issue 17.85 11.57 88 52868 149387 50402781
Mental status changes 17.62 11.57 80 52876 36192 50515976
Abortion spontaneous 17.55 11.57 11 52945 41761 50510407
Acquired cystic kidney disease 17.47 11.57 5 52951 49 50552119
Intentional product misuse 17.41 11.57 14 52942 46720 50505448
Anuria 17.16 11.57 37 52919 11207 50540961
Coronary artery disease 16.97 11.57 5 52951 29721 50522447
Lymphocyte count decreased 16.70 11.57 63 52893 26244 50525924
Morbid thoughts 16.45 11.57 9 52947 533 50551635
Streptococcal bacteraemia 16.38 11.57 13 52943 1445 50550723
Impaired healing 16.36 11.57 30 52926 69756 50482412
Clostridium difficile colitis 16.17 11.57 48 52908 17694 50534474
Psoriasis 15.87 11.57 30 52926 68970 50483198
Multiple sclerosis relapse 15.84 11.57 13 52943 42951 50509217
Drug reaction with eosinophilia and systemic symptoms 15.83 11.57 5 52951 28419 50523749
Parkinsonism 15.73 11.57 31 52925 8816 50543352
Blood pressure fluctuation 15.65 11.57 9 52947 35814 50516354
Enteritis 15.57 11.57 27 52929 6968 50545200
Therapeutic response decreased 15.39 11.57 16 52940 47215 50504953
Pancreatic carcinoma recurrent 15.35 11.57 5 52951 78 50552090
Pregnancy 15.11 11.57 6 52950 29571 50522597
Chills 15 11.57 161 52795 96526 50455642
Oesophagitis 14.95 11.57 39 52917 13344 50538824
Intentional self-injury 14.93 11.57 3 52953 23109 50529059
Ovarian cancer recurrent 14.75 11.57 10 52946 872 50551296
Haematocrit decreased 14.71 11.57 74 52882 34902 50517266
Hypermagnesaemia 14.63 11.57 10 52946 884 50551284
Dyssomnia 14.48 11.57 4 52952 34 50552134
Dyspepsia 14.23 11.57 129 52827 73968 50478200
Asthma 14.19 11.57 47 52909 89290 50462878
Bacteraemia 14.07 11.57 40 52916 14393 50537775
Acute myeloid leukaemia 13.94 11.57 41 52915 15033 50537135
Ascites 13.79 11.57 74 52882 35787 50516381
Hypomagnesaemia 13.51 11.57 54 52902 23102 50529066
Heart rate decreased 13.51 11.57 11 52945 36486 50515682
Diabetes mellitus 13.45 11.57 19 52937 49014 50503154
Lymph node pain 13.39 11.57 11 52945 1284 50550884
Cataract 13.32 11.57 90 52866 47210 50504958
Systemic inflammatory response syndrome 13.26 11.57 21 52935 5028 50547140
Embolism 13.10 11.57 25 52931 6943 50545225
Inflammation 12.87 11.57 25 52931 56887 50495281
Alopecia 12.78 11.57 180 52776 244867 50307301
Dizziness 12.66 11.57 462 52494 345907 50206261
Plasmacytoma 12.64 11.57 14 52942 2371 50549797
Dysphagia 12.45 11.57 130 52826 77388 50474780
Palpitations 12.25 11.57 152 52804 94354 50457814
Urinary tract infection 12.25 11.57 314 52642 223706 50328462
Enterocolitis infectious 12.13 11.57 11 52945 1467 50550701
Wrong technique in product usage process 12.02 11.57 25 52931 55485 50496683
Stomatitis 11.88 11.57 160 52796 101184 50450984
Non-small cell lung cancer 11.85 11.57 15 52941 2922 50549246
Gastrointestinal injury 11.74 11.57 7 52949 488 50551680
Osteoporosis 11.71 11.57 18 52938 44861 50507307
Neutropenic sepsis 11.70 11.57 37 52919 14110 50538058
Sedation 11.61 11.57 9 52947 30601 50521567
Lethargy 11.59 11.57 90 52866 49342 50502826

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 355.41 12.47 535 33626 111705 29428661
Fatigue 194.44 12.47 800 33361 316021 29224345
Plasma cell myeloma 184.77 12.47 221 33940 36894 29503472
Disease progression 135.66 12.47 295 33866 81621 29458745
Nausea 134.81 12.47 674 33487 288581 29251785
Dehydration 128.02 12.47 355 33806 114393 29425973
Death 101.51 12.47 708 33453 341376 29198990
Malignant neoplasm progression 98.09 12.47 244 33917 73615 29466751
Diarrhoea 95.99 12.47 684 33477 332014 29208352
Pneumonia 91.60 12.47 657 33504 319515 29220851
Vomiting 90.50 12.47 483 33678 211777 29328589
Decreased appetite 84.59 12.47 362 33799 144980 29395386
Drug abuse 72.81 12.47 5 34156 79878 29460488
Drug interaction 69.95 12.47 75 34086 197310 29343056
White blood cell count decreased 68.58 12.47 232 33929 83130 29457236
Drug ineffective 64.14 12.47 211 33950 362959 29177407
Toxicity to various agents 63.75 12.47 64 34097 173597 29366769
Neuropathy peripheral 58.69 12.47 198 33963 70829 29469537
Full blood count decreased 57.26 12.47 81 34080 15911 29524455
Constipation 55.64 12.47 270 33891 113890 29426476
Condition aggravated 54.73 12.47 53 34108 146242 29394124
Platelet count decreased 50.59 12.47 247 33914 104425 29435941
Completed suicide 48.12 12.47 22 34139 90224 29450142
Meconium abnormal 43.94 12.47 11 34150 54 29540312
Neutropenia 43.80 12.47 281 33880 131430 29408936
Neutrophil count decreased 40.98 12.47 127 34034 43440 29496926
Overdose 40.20 12.47 21 34140 79798 29460568
Hospice care 38.95 12.47 38 34123 5030 29535336
Rash 38.06 12.47 360 33801 189459 29350907
Neoplasm progression 37.78 12.47 73 34088 18539 29521827
Failure to thrive 36.95 12.47 45 34116 7639 29532727
Small intestinal obstruction 36.58 12.47 59 34102 13002 29527364
Cytokine release syndrome 35.03 12.47 58 34103 13061 29527305
Back pain 32.61 12.47 216 33945 102068 29438298
Necrotising enterocolitis neonatal 31.15 12.47 11 34150 200 29540166
Deep vein thrombosis 31.02 12.47 140 34021 57259 29483107
Product use in unapproved indication 30.71 12.47 33 34128 86842 29453524
Asthenia 30.51 12.47 381 33780 214869 29325497
Therapeutic product effect incomplete 29.39 12.47 5 34156 39300 29501066
Intentional overdose 28.60 12.47 5 34156 38523 29501843
Muscle spasms 28.19 12.47 149 34012 64933 29475433
Sepsis 27.76 12.47 269 33892 142413 29397953
Coma 25.48 12.47 7 34154 39443 29500923
Bradycardia 25.42 12.47 23 34138 65606 29474760
Adverse drug reaction 25.40 12.47 73 34088 23947 29516419
Rhabdomyolysis 25.15 12.47 20 34141 60788 29479578
Intentional product misuse 24.65 12.47 5 34156 34656 29505710
Suicide attempt 24.10 12.47 5 34156 34105 29506261
Off label use 24.04 12.47 227 33934 300573 29239793
Thrombosis 24.01 12.47 106 34055 42939 29497427
Pulmonary embolism 24 12.47 161 34000 76373 29463993
General physical health deterioration 23.91 12.47 52 34109 102805 29437561
Ageusia 23.17 12.47 39 34122 8899 29531467
Injection site pain 22.42 12.47 5 34156 32441 29507925
Cardiac failure 21.09 12.47 37 34124 79250 29461116
Laboratory test abnormal 20.93 12.47 57 34104 18128 29522238
Hiccups 20.82 12.47 37 34124 8816 29531550
Oral pain 20.74 12.47 38 34123 9269 29531097
Spinal cord compression 20.60 12.47 23 34138 3559 29536807
Dysgeusia 20.30 12.47 65 34096 22609 29517757
Psoriasis 20.29 12.47 6 34155 32221 29508145
Coronary artery disease 20.28 12.47 13 34148 44177 29496189
Hyponatraemia 19.85 12.47 140 34021 67493 29472873
Bacteraemia 19.62 12.47 52 34109 16271 29524095
Wrong technique in product usage process 19.52 12.47 6 34155 31422 29508944
Fluid imbalance 19.11 12.47 8 34153 234 29540132
C-reactive protein increased 19.01 12.47 14 34147 44249 29496117
Rheumatoid arthritis 18.47 12.47 7 34154 32145 29508221
Weight decreased 18.38 12.47 260 33901 150645 29389721
Treatment failure 18.18 12.47 10 34151 36929 29503437
Pleural effusion 17.26 12.47 142 34019 71766 29468600
Hypophagia 17.04 12.47 58 34103 20814 29519552
Drug reaction with eosinophilia and systemic symptoms 16.24 12.47 6 34155 27986 29512380
Diaphragmatic rupture 16.08 12.47 4 34157 19 29540347
Clostridium difficile infection 16.05 12.47 48 34113 16093 29524273
Dystonia 15.96 12.47 35 34126 9714 29530652
Bacillus bacteraemia 15.85 12.47 5 34156 63 29540303
Mental status changes 15.83 12.47 81 34080 34846 29505520
Inappropriate schedule of product administration 15.59 12.47 17 34144 44455 29495911
Plasma cell myeloma recurrent 15.21 12.47 20 34141 3663 29536703
Anaemia 14.98 12.47 320 33841 200631 29339735
Mixed dementia 14.92 12.47 7 34154 270 29540096
Laparotomy 14.85 12.47 7 34154 273 29540093
Inferior vena caval occlusion 14.77 12.47 4 34157 28 29540338
Immune effector cell-associated neurotoxicity syndrome 14.76 12.47 13 34148 1511 29538855
Oesophagitis 14.35 12.47 38 34123 11885 29528481
Haematochezia 14.27 12.47 13 34148 36970 29503396
Temperature intolerance 13.87 12.47 17 34144 2904 29537462
Peripheral swelling 13.79 12.47 123 34038 63616 29476750
Cholestasis 13.66 12.47 5 34156 23457 29516909
Red blood cell count decreased 13.49 12.47 62 34099 25540 29514826
Abdominal distension 13.44 12.47 95 34066 45816 29494550
Pancytopenia 13.40 12.47 151 34010 83017 29457349
Pneumonitis 13.38 12.47 66 34095 27978 29512388
Hypoxia 13.27 12.47 97 34064 47282 29493084
Wrist deformity 13.25 12.47 7 34154 349 29540017
Cholangiocarcinoma 13.20 12.47 10 34151 940 29539426
Therapeutic response decreased 13.19 12.47 6 34155 24705 29515661
Seizure 13.17 12.47 59 34102 93064 29447302
Tooth disorder 13.16 12.47 32 34129 9497 29530869
Blood potassium decreased 13.09 12.47 44 34117 15690 29524676
Therapeutic product effect decreased 13.06 12.47 9 34152 29442 29510924
Drug dependence 13.04 12.47 4 34157 20977 29519389
Oral candidiasis 12.73 12.47 34 34127 10688 29529678
Myocardial infarction 12.70 12.47 75 34086 110221 29430145
Respiratory arrest 12.70 12.47 7 34154 25826 29514540
Enterocolitis infectious 12.49 12.47 11 34150 1278 29539088

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 739.58 11.25 958 68449 186699 64242626
Disease progression 322.24 11.25 560 68847 141120 64288205
Dehydration 316.34 11.25 711 68696 216052 64213273
Plasma cell myeloma 279.32 11.25 294 69113 45781 64383544
Nausea 250.30 11.25 1569 67838 784231 63645094
Drug ineffective 230.03 11.25 344 69063 839903 63589422
Vomiting 229.48 11.25 1183 68224 549934 63879391
Fatigue 227.14 11.25 1477 67930 747253 63682072
Diarrhoea 225.53 11.25 1436 67971 721268 63708057
White blood cell count decreased 213.75 11.25 503 68904 157334 64271991
Platelet count decreased 147.69 11.25 456 68951 167255 64262070
Toxicity to various agents 142.19 11.25 110 69297 363403 64065922
Malignant neoplasm progression 141.20 11.25 349 69058 112522 64316803
Death 120.22 11.25 909 68498 481796 63947529
Pneumonia 116.25 11.25 1011 68396 558565 63870760
Decreased appetite 114.55 11.25 601 68806 280688 64148637
Neutropenia 112.42 11.25 533 68874 239091 64190234
Constipation 111.90 11.25 516 68891 228821 64200504
Drug abuse 108.72 11.25 9 69398 132365 64296960
Neoplasm progression 102.31 11.25 169 69238 40795 64388530
Contraindicated product administered 102.16 11.25 3 69404 107826 64321499
Neutrophil count decreased 100.01 11.25 242 69165 76954 64352371
Completed suicide 99.58 11.25 59 69348 224355 64204970
Synovitis 93.00 11.25 3 69404 99087 64330238
Asthenia 91.67 11.25 779 68628 427265 64002060
Small intestinal obstruction 84.25 11.25 115 69292 23458 64405867
Condition aggravated 81.97 11.25 174 69233 372252 64057073
Cytokine release syndrome 78.07 11.25 104 69303 20725 64408600
Failure to thrive 76.98 11.25 74 69333 10330 64418995
Arthropathy 76.65 11.25 18 69389 120949 64308376
Blood magnesium decreased 75.92 11.25 84 69323 13821 64415504
Therapeutic product effect decreased 75.43 11.25 16 69391 115335 64313990
Full blood count decreased 74.48 11.25 106 69301 22476 64406849
Therapeutic product effect incomplete 72.69 11.25 12 69395 103470 64325855
Abdominal pain 71.86 11.25 578 68829 311797 64117528
Hospice care 71.61 11.25 62 69345 7563 64421762
Sepsis 70.77 11.25 457 68950 229884 64199441
Thrombosis 70.57 11.25 201 69206 70441 64358884
Drug interaction 68.65 11.25 183 69224 361900 64067425
Pleural effusion 68.61 11.25 294 69113 126265 64303060
Neovascularisation 68.09 11.25 30 69377 1073 64428252
Joint swelling 66.84 11.25 80 69327 215302 64214023
Off label use 66.07 11.25 405 69002 632401 63796924
Clostridium difficile infection 64.57 11.25 129 69278 36034 64393291
Coma 64.19 11.25 9 69398 87606 64341719
Neuropathy peripheral 58.38 11.25 266 69141 117259 64312066
Systemic lupus erythematosus 56.79 11.25 8 69399 77604 64351721
Intentional overdose 55.77 11.25 14 69393 89930 64339395
Injection site pain 55.76 11.25 25 69382 111383 64317942
Heart rate abnormal 53.58 11.25 44 69363 4991 64424334
General physical health deterioration 53.34 11.25 86 69321 204339 64224986
Overdose 53.06 11.25 56 69351 159510 64269815
Hyponatraemia 49.05 11.25 300 69107 148039 64281286
Pancytopenia 48.77 11.25 292 69115 143017 64286308
Carbohydrate antigen 125 increased 46.95 11.25 28 69379 1900 64427425
Thrombocytopenia 45.50 11.25 403 69004 223398 64205927
Hair colour changes 44.84 11.25 35 69372 3692 64425633
Colitis 44.73 11.25 152 69255 58522 64370803
Pneumonitis 44.29 11.25 137 69270 50228 64379097
Akathisia 43.95 11.25 58 69349 11452 64417873
Drug intolerance 43.70 11.25 85 69322 187907 64241418
Palmar-plantar erythrodysaesthesia syndrome 42.39 11.25 95 69312 28724 64400601
Lymphadenitis 42.23 11.25 34 69373 3751 64425574
Suicide attempt 42.23 11.25 12 69395 70995 64358330
Pulmonary embolism 41.65 11.25 285 69122 146071 64283254
Deep vein thrombosis 41.50 11.25 223 69184 104959 64324366
Back pain 41.24 11.25 431 68976 249740 64179585
Red blood cell count decreased 41.06 11.25 130 69277 48256 64381069
Hypophagia 39.87 11.25 113 69294 39474 64389851
Rheumatoid arthritis 39.30 11.25 73 69334 164221 64265104
Gangrene 37.78 11.25 43 69364 7295 64422030
Oral pain 37.54 11.25 88 69319 27405 64401920
Anaemia 37.22 11.25 593 68814 378087 64051238
Weight decreased 36.25 11.25 468 68939 285271 64144054
Arterial occlusive disease 35.85 11.25 41 69366 6992 64422333
Dysgeusia 35.09 11.25 121 69286 46926 64382399
Intentional product misuse 34.97 11.25 17 69390 72278 64357047
C-reactive protein increased 34.21 11.25 31 69376 94878 64334447
Pyrexia 33.91 11.25 813 68594 557831 63871494
Mental status changes 33.05 11.25 142 69265 61020 64368305
Lower respiratory tract infection 32.81 11.25 32 69375 94582 64334743
Nasopharyngitis 32.80 11.25 105 69302 195968 64233357
Coronary artery disease 32.77 11.25 12 69395 60421 64368904
Bacteraemia 32.33 11.25 82 69325 26829 64402496
Injection site erythema 32.24 11.25 18 69389 70782 64358543
Hypoxia 32.17 11.25 183 69224 87966 64341359
Alopecia areata 31.62 11.25 20 69387 1508 64427817
Injection site reaction 31.48 11.25 6 69401 46658 64382667
Pericarditis 31.32 11.25 14 69393 62502 64366823
Haemoglobin decreased 31.15 11.25 334 69073 194729 64234596
Drug reaction with eosinophilia and systemic symptoms 30.72 11.25 10 69397 54207 64375118
Mucosal inflammation 30.57 11.25 141 69266 62443 64366882
Oesophagitis 30.37 11.25 70 69337 21560 64407765
Rectal cancer metastatic 30.29 11.25 13 69394 436 64428889
Blood potassium decreased 30.21 11.25 104 69303 40295 64389030
Hair texture abnormal 29.38 11.25 25 69382 2979 64426346
Musculoskeletal stiffness 27.51 11.25 57 69350 123149 64306176
Hepatic enzyme increased 27.45 11.25 62 69345 129881 64299444
Rhabdomyolysis 27.45 11.25 35 69372 91691 64337634
Dry skin 27.04 11.25 118 69289 51043 64378282
Bradycardia 26.98 11.25 54 69353 118165 64311160
Blood pressure fluctuation 26.97 11.25 11 69396 51860 64377465
Injection site swelling 26.49 11.25 6 69401 41347 64387978
Psoriatic arthropathy 26.32 11.25 7 69400 43274 64386051
Immune effector cell-associated neurotoxicity syndrome 26.21 11.25 22 69385 2573 64426752
Enterocolitis infectious 25.11 11.25 21 69386 2443 64426882
Glossodynia 24.69 11.25 20 69387 64676 64364649
Cardiac failure 23.47 11.25 69 69338 132304 64297021
Eosinophilia 23.46 11.25 6 69401 38070 64391255
Red blood cell sedimentation rate increased 23.37 11.25 3 69404 31232 64398093
Red cell distribution width increased 23.29 11.25 45 69362 12264 64417061
Weight increased 22.96 11.25 135 69272 213213 64216112
Hypokalaemia 22.95 11.25 216 69191 121687 64307638
Swelling 22.67 11.25 92 69315 160126 64269199
Non-small cell lung cancer 22.42 11.25 27 69380 4863 64424462
Folliculitis 22.24 11.25 3 69404 30074 64399251
Paradoxical drug reaction 22.08 11.25 30 69377 6090 64423235
Discomfort 22.05 11.25 33 69374 80845 64348480
Performance status decreased 21.99 11.25 28 69379 5336 64423989
Hepatitis 21.62 11.25 11 69396 45571 64383754
Mobility decreased 21.54 11.25 37 69370 85803 64343522
Cholestasis of pregnancy 21.40 11.25 13 69394 912 64428413
Systemic inflammatory response syndrome 21.33 11.25 39 69368 10196 64419129
Hypersensitivity 21.31 11.25 124 69283 196328 64232997
Infusion related reaction 21.10 11.25 98 69309 164369 64264956
Heart rate decreased 21.04 11.25 17 69390 55050 64374275
Taste disorder 21.01 11.25 37 69370 9396 64419929
Muscle twitching 20.88 11.25 56 69351 18942 64410383
Ageusia 20.84 11.25 46 69361 13767 64415558
Cytomegalovirus infection 20.83 11.25 7 69400 37192 64392133
Treatment failure 20.63 11.25 61 69346 116755 64312570
Pain 20.48 11.25 447 68960 553064 63876261
Asthma 20.46 11.25 45 69362 95180 64334145
Enteritis 20.27 11.25 42 69365 12035 64417290
Wound 20.09 11.25 32 69375 76445 64352880
Madarosis 19.99 11.25 18 69389 2312 64427013
Psoriasis 19.80 11.25 29 69378 71674 64357651
Sedation 19.67 11.25 10 69397 41452 64387873
Medication error 19.63 11.25 15 69392 49951 64379374
Blood creatine increased 19.38 11.25 33 69374 8159 64421166
Hypermagnesaemia 19.37 11.25 13 69394 1084 64428241
Streptococcal bacteraemia 19.34 11.25 20 69387 3047 64426278
Blood pressure systolic increased 19.23 11.25 15 69392 49438 64379887
Wrong technique in product usage process 19.22 11.25 25 69382 64949 64364376
Intentional self-injury 19.04 11.25 4 69403 29040 64400285
Metastatic renal cell carcinoma 18.91 11.25 17 69390 2179 64427146
Hypophosphataemia 18.89 11.25 46 69361 14674 64414651
Product use in unapproved indication 18.87 11.25 112 69295 176506 64252819
Embolism 18.75 11.25 41 69366 12194 64417131
Loss of personal independence in daily activities 18.39 11.25 31 69376 72423 64356902
Klebsiella bacteraemia 17.99 11.25 17 69390 2323 64427002
Lymphocyte count decreased 17.92 11.25 89 69318 40610 64388715
Depressed level of consciousness 17.90 11.25 38 69369 81398 64347927
Haematocrit decreased 17.70 11.25 110 69297 54545 64374780
Therapeutic response decreased 17.69 11.25 18 69389 52170 64377155
Dysphagia 17.55 11.25 184 69223 106628 64322697
Inflammation 17.46 11.25 27 69380 65273 64364052
Stomatitis 17.17 11.25 187 69220 109418 64319907
Cancer pain 17.10 11.25 22 69385 4235 64425090
Cholestasis 16.96 11.25 14 69393 44858 64384467
Injection site bruising 16.92 11.25 9 69398 36364 64392961
Injection site pruritus 16.67 11.25 10 69397 37816 64391509
Acquired cystic kidney disease 16.65 11.25 5 69402 57 64429268
Dizziness 16.40 11.25 591 68816 429572 63999753
Ill-defined disorder 16.34 11.25 14 69393 44038 64385287
Cholangitis 16.32 11.25 36 69371 10766 64418559
Autoimmune nephritis 16.13 11.25 9 69398 538 64428787
Clostridium difficile colitis 16.11 11.25 65 69342 27158 64402167
Arthralgia 16.09 11.25 358 69049 441902 63987423
Osteoporosis 16.07 11.25 13 69394 42067 64387258
Hypoglycaemia 15.83 11.25 47 69360 89845 64339480
Retching 15.80 11.25 44 69363 15212 64414113
Product use issue 15.79 11.25 97 69310 151618 64277707
Exposure during pregnancy 15.65 11.25 38 69369 77637 64351688
Impaired healing 15.23 11.25 26 69381 60447 64368878
Fluid imbalance 15.19 11.25 8 69399 426 64428899
Mixed dementia 15.09 11.25 7 69400 283 64429042
Drug hypersensitivity 14.94 11.25 348 69059 237467 64191858
Spinal cord compression 14.87 11.25 24 69383 5679 64423646
Anaphylactic shock 14.86 11.25 7 69400 30321 64399004
Lymph node pain 14.78 11.25 12 69395 1340 64427985
Diabetes mellitus 14.62 11.25 31 69376 66443 64362882
Dystonia 14.48 11.25 49 69358 18816 64410509
Inferior vena caval occlusion 14.48 11.25 4 69403 33 64429292
Therapeutic drug monitoring analysis incorrectly performed 14.42 11.25 6 69401 186 64429139
Gastric disorder 14.42 11.25 66 69341 29131 64400194
Stress 14.37 11.25 27 69380 60507 64368818
Tumour marker increased 14.13 11.25 18 69389 3432 64425893
Respiratory arrest 14.08 11.25 22 69385 52963 64376362
Hyperglycaemia 14.06 11.25 113 69294 60855 64368470
Feeding disorder 14.06 11.25 38 69369 12911 64416414
Diabetes mellitus inadequate control 13.84 11.25 3 69404 21318 64408007
Pancreatic carcinoma recurrent 13.70 11.25 5 69402 108 64429217
Cardiogenic shock 13.70 11.25 9 69398 32418 64396907
Inappropriate schedule of product administration 13.68 11.25 52 69355 92234 64337091
Renal cell carcinoma 13.67 11.25 24 69383 6080 64423245
Arthritis infective 13.67 11.25 26 69381 7004 64422321
Hypoalbuminaemia 13.65 11.25 46 69361 17628 64411697
Bacillus bacteraemia 13.53 11.25 5 69402 112 64429213
Skull fracture 13.41 11.25 12 69395 1529 64427796
Oral candidiasis 13.40 11.25 55 69352 23157 64406168
Myocardial infarction 13.39 11.25 114 69293 165707 64263618
Mean cell haemoglobin concentration decreased 13.20 11.25 18 69389 3666 64425659
Agranulocytosis 13.17 11.25 13 69394 38216 64391109
Muscle spasms 13.12 11.25 219 69188 140804 64288521
Abdominal infection 13.10 11.25 16 69391 2924 64426401
Drug dependence 13.09 11.25 10 69397 33302 64396023
Multiple sclerosis relapse 13.04 11.25 15 69392 41120 64388205
Colon cancer metastatic 12.96 11.25 13 69394 1910 64427415
Atrial fibrillation 12.87 11.25 257 69150 170832 64258493
Pancreatic carcinoma 12.87 11.25 32 69375 10341 64418984
Fear 12.77 11.25 3 69404 20168 64409157
Acute myeloid leukaemia 12.77 11.25 61 69346 27402 64401923
Hiccups 12.75 11.25 28 69379 8348 64420977
Lymphadenopathy 12.72 11.25 90 69317 46596 64382729
Therapy non-responder 12.68 11.25 33 69374 65866 64363459
Irritable bowel syndrome 12.54 11.25 13 69394 37356 64391969
Skin exfoliation 12.51 11.25 87 69320 44798 64384527
Urinary tract infection 12.49 11.25 332 69075 231264 64198061
Metastases to liver 12.48 11.25 55 69352 23886 64405439
Pancreatic carcinoma metastatic 12.47 11.25 17 69390 3461 64425864
Aggression 12.47 11.25 19 69388 46213 64383112
Cholangiocarcinoma 12.44 11.25 13 69394 2005 64427320
Maternal exposure during pregnancy 12.37 11.25 57 69350 95827 64333498
Lung squamous cell carcinoma metastatic 12.32 11.25 4 69403 60 64429265
Haematochezia 12.20 11.25 34 69373 66339 64362986
Oesophageal ulcer 12.11 11.25 23 69384 6187 64423138
Obstructive airways disorder 11.92 11.25 5 69402 23180 64406145
Liver injury 11.74 11.25 9 69398 29923 64399402
Hypovolaemia 11.69 11.25 40 69367 15446 64413879
Hypogeusia 11.66 11.25 11 69396 1500 64427825
Injury 11.59 11.25 27 69380 55965 64373360
Lymphatic disorder 11.56 11.25 6 69401 310 64429015
Spasmodic dysphonia 11.48 11.25 5 69402 174 64429151
Oxygen saturation decreased 11.42 11.25 68 69339 107108 64322217
Morbid thoughts 11.39 11.25 8 69399 718 64428607
Fibromyalgia 11.36 11.25 13 69394 35718 64393607
Drug level increased 11.36 11.25 12 69395 34184 64395141
Pneumothorax 11.32 11.25 54 69353 24244 64405081
Chills 11.28 11.25 209 69198 137055 64292270
Blood sodium decreased 11.27 11.25 62 69345 29420 64399905

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05AB04 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Phenothiazines with piperazine structure
FDA CS M0016525 Phenothiazines
MeSH PA D000932 Antiemetics
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D015259 Dopamine Agents
MeSH PA D018492 Dopamine Antagonists
MeSH PA D005765 Gastrointestinal Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
CHEBI has role CHEBI:37890 alpha-adrenergic receptor blockaders
CHEBI has role CHEBI:48561 dopaminergic antagonists
CHEBI has role CHEBI:48873 acetylcholine receptor antagonist
CHEBI has role CHEBI:50919 antiemetico
CHEBI has role CHEBI:65190 typical antipsychotic drugs
CHEBI has role CHEBI:76779 post-proline endopeptidase inhibitors
CHEBI has role CHEBI:131787 D2R antagonist
FDA EPC N0000175746 Phenothiazine

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Nausea and vomiting indication 16932000
Schizophrenia indication 58214004 DOID:5419
Nonpsychotic Anxiety indication
Prolonged-Severe Nausea and Vomiting indication
Migraine off-label use 37796009 DOID:6364
Chemotherapy-induced nausea and vomiting off-label use 236084000
Brain damage contraindication 2470005
Tachyarrhythmia contraindication 6285003
Urinary tract obstruction contraindication 7163005 DOID:5200
Alcoholism contraindication 7200002
Organophosphate poisoning contraindication 8260003
Weight gain finding contraindication 8943002
Severe chronic ulcerative colitis contraindication 14311001
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Chronic disease of respiratory system contraindication 17097001
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Toxic megacolon contraindication 28536002 DOID:1770
Orthostatic hypotension contraindication 28651003
Atony of colon contraindication 29479008
Torsades de pointes contraindication 31722008
Parkinsonism contraindication 32798002
Hyperthyroidism contraindication 34486009 DOID:7998
Hypertensive disorder contraindication 38341003 DOID:10763
Complete trisomy 21 syndrome contraindication 41040004 DOID:14250
Conduction disorder of the heart contraindication 44808001
Achalasia of esophagus contraindication 45564002 DOID:9164
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Paralytic ileus contraindication 55525008 DOID:8442
Peptic reflux disease contraindication 57643001
Ulcerative colitis contraindication 64766004 DOID:8577
Drug AND/OR toxin-induced diarrhea contraindication 65979008
Extrapyramidal disease contraindication 76349003
Spastic paralysis contraindication 78403003
Disturbance of salivary secretion contraindication 78948009
Hyperglycemia contraindication 80394007 DOID:4195
Hiatal hernia contraindication 84089009 DOID:12642
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Stupor contraindication 89458003
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Tardive dyskinesia contraindication 102449007
Prolonged QT interval contraindication 111975006
Gastrointestinal obstruction contraindication 126765001
Acute disease of cardiovascular system contraindication 128487001
Autonomic dysreflexia contraindication 129618003
Bleeding contraindication 131148009
Angina pectoris contraindication 194828000
Myocardial dysfunction contraindication 233928007
Disease of liver contraindication 235856003 DOID:409
Bladder outflow obstruction contraindication 236645006
Metabolic syndrome X contraindication 237602007 DOID:14221
Hyperprolactinemia contraindication 237662005 DOID:12700
Pyloric obstruction contraindication 244815007
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Drowsy contraindication 271782001
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Coma contraindication 371632003
At risk for aspiration contraindication 371736008
Angle-closure glaucoma contraindication 392291006 DOID:13550
Visual impairment contraindication 397540003
Gastric ulcer contraindication 397825006 DOID:10808
Breastfeeding (mother) contraindication 413712001
Chronic lung disease contraindication 413839001
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Congenital long QT syndrome contraindication 442917000
Carcinoma of female breast contraindication 447782002




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

ProductApplicantIngredients
Darbazine Spansule Capsule No.1 Zoetis Inc. 2
Darbazine Injectable Zoetis Inc. 2
Neo-Darbazine Spansule Capsule No.1, Neo-Darbazine Spansule Capsule No.3 Zoetis Inc. 3

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.74 Basic
pKa2 4.74 Basic
pKa3 2.21 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D(2) dopamine receptor GPCR ANTAGONIST Ki 8.76 WOMBAT-PK CHEMBL
D(3) dopamine receptor GPCR ANTAGONIST Ki 8.61 WOMBAT-PK IUPHAR
Alpha-2A adrenergic receptor GPCR Ki 7.20 DRUG MATRIX
Sigma non-opioid intracellular receptor 1 Membrane receptor Ki 7.64 DRUG MATRIX
Potassium voltage-gated channel subfamily H member 2 Ion channel Ki 5.82 DRUG MATRIX
Sodium-dependent serotonin transporter Transporter Ki 6.21 DRUG MATRIX
Sodium-dependent noradrenaline transporter Transporter Ki 6.40 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 5.23 PDSP
5-hydroxytryptamine receptor 2A GPCR Ki 7.82 WOMBAT-PK
5-hydroxytryptamine receptor 2B GPCR Ki 7.19 DRUG MATRIX
5-hydroxytryptamine receptor 2C GPCR Ki 6.91 WOMBAT-PK
5-hydroxytryptamine receptor 6 GPCR Ki 6.91 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR Ki 7.62 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 8.32 DRUG MATRIX
Histamine H1 receptor GPCR Ki 7.72 WOMBAT-PK
Muscarinic acetylcholine receptor M1 GPCR Ki 6.61 DRUG MATRIX
Muscarinic acetylcholine receptor M2 GPCR Ki 5.96 DRUG MATRIX
Muscarinic acetylcholine receptor M3 GPCR Ki 6.49 DRUG MATRIX
Muscarinic acetylcholine receptor M4 GPCR Ki 6.72 DRUG MATRIX
Muscarinic acetylcholine receptor M5 GPCR Ki 6.80 DRUG MATRIX
Alpha-2C adrenergic receptor GPCR Ki 7.92 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 5.86 DRUG MATRIX
Cytochrome P450 2D6 Enzyme IC50 6.52 DRUG MATRIX
D(4) dopamine receptor GPCR Ki 7.17 WOMBAT-PK
Alpha-1D adrenergic receptor GPCR Ki 7.89 DRUG MATRIX
Cytochrome P450 1A2 Enzyme IC50 5.70 DRUG MATRIX
Tyrosine-protein kinase Fyn Kinase IC50 5.25 DRUG MATRIX
Solute carrier family 22 member 1 Transporter IC50 4.30 CHEMBL
D(1A) dopamine receptor GPCR Ki 7.11 DRUG MATRIX
Alpha-1B adrenergic receptor GPCR Ki 7.31 DRUG MATRIX
5-hydroxytryptamine receptor 1B GPCR Ki 5.92 DRUG MATRIX
Membrane-associated progesterone receptor component 1 Membrane receptor Ki 6.38 DRUG MATRIX
Alpha-1A adrenergic receptor GPCR IC50 7.49 CHEMBL
5-hydroxytryptamine receptor 1A GPCR IC50 6.02 CHEMBL
5-hydroxytryptamine receptor 4 GPCR Ki 6.71 DRUG MATRIX
Pleiotropic ABC efflux transporter of multiple drugs Transporter IC50 5.77 CHEMBL

External reference:

IDSource
4018001 VUID
N0000146346 NUI
D00479 KEGG_DRUG
84-02-6 SECONDARY_CAS_RN
1257-78-9 SECONDARY_CAS_RN
4017999 VANDF
4018000 VANDF
4018001 VANDF
C0033229 UMLSCUI
CHEBI:8435 CHEBI
P77 PDB_CHEM_ID
CHEMBL728 ChEMBL_ID
DB00433 DRUGBANK_ID
CHEMBL1200587 ChEMBL_ID
CHEMBL1314751 ChEMBL_ID
CHEMBL1201154 ChEMBL_ID
D011346 MESH_DESCRIPTOR_UI
4917 PUBCHEM_CID
7279 IUPHAR_LIGAND_ID
699 INN_ID
YHP6YLT61T UNII
235739 RXNORM
2073 MMSL
5361 MMSL
5362 MMSL
5363 MMSL
6416 MMSL
6417 MMSL
d00355 MMSL
001478 NDDF
001479 NDDF
001480 NDDF
003466 NDDF
22827004 SNOMEDCT_US
372853006 SNOMEDCT_US
3823007 SNOMEDCT_US
395843006 SNOMEDCT_US
79129001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Prochlorperazine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0378-5105 TABLET, FILM COATED 5 mg ORAL ANDA 14 sections
Prochlorperazine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0378-5110 TABLET, FILM COATED 10 mg ORAL ANDA 14 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 0440-8190 TABLET 5 mg ORAL ANDA 12 sections
Compro HUMAN PRESCRIPTION DRUG LABEL 1 0574-7226 SUPPOSITORY 25 mg RECTAL ANDA 19 sections
Prochlorperazine Edisylate HUMAN PRESCRIPTION DRUG LABEL 1 0641-6135 INJECTION 5 mg INTRAMUSCULAR ANDA 18 sections
Prochlorperazine Edisylate HUMAN PRESCRIPTION DRUG LABEL 1 0641-6135 INJECTION 5 mg INTRAMUSCULAR ANDA 18 sections
Prochlorperazine HUMAN PRESCRIPTION DRUG LABEL 1 0713-0135 SUPPOSITORY 25 mg RECTAL ANDA 13 sections
Prochlorperazine HUMAN PRESCRIPTION DRUG LABEL 1 0713-0135 SUPPOSITORY 25 mg RECTAL ANDA 13 sections
Prochlorperazine Edisylate HUMAN PRESCRIPTION DRUG LABEL 1 0713-0351 INJECTION 5 mg INTRAMUSCULAR ANDA 13 sections
Prochlorperazine Edisylate HUMAN PRESCRIPTION DRUG LABEL 1 0713-0351 INJECTION 5 mg INTRAMUSCULAR ANDA 13 sections
Prochlorperazine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0781-5020 TABLET, FILM COATED 5 mg ORAL ANDA 18 sections
Prochlorperazine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 0781-5021 TABLET, FILM COATED 10 mg ORAL ANDA 18 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 10544-281 TABLET 10 mg ORAL ANDA 12 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 10544-511 TABLET 5 mg ORAL ANDA 12 sections
Prochlorperazine Edisylate HUMAN PRESCRIPTION DRUG LABEL 1 14789-700 INJECTION 5 mg INTRAMUSCULAR ANDA 18 sections
PROCHLORPERAZINE HUMAN PRESCRIPTION DRUG LABEL 1 16590-327 TABLET 10 mg ORAL ANDA 10 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 21695-571 TABLET 5 mg ORAL ANDA 12 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 21695-572 TABLET 10 mg ORAL ANDA 12 sections
Prochlorperazine Edisylate HUMAN PRESCRIPTION DRUG LABEL 1 23155-294 INJECTION 5 mg INTRAMUSCULAR ANDA 13 sections
PROCHLORPERAZINE EDISYLATE HUMAN PRESCRIPTION DRUG LABEL 1 23155-497 INJECTION 5 mg INTRAMUSCULAR ANDA 12 sections
Prochlorperazine Edisylate HUMAN PRESCRIPTION DRUG LABEL 1 23155-523 INJECTION 5 mg INTRAMUSCULAR ANDA 13 sections
PROCHLORPERAZINE EDISYLATE HUMAN PRESCRIPTION DRUG LABEL 1 25021-790 INJECTION 5 mg INTRAVENOUS ANDA 18 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 33261-141 TABLET 5 mg ORAL ANDA 12 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 33261-550 TABLET 10 mg ORAL ANDA 12 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 42291-728 TABLET 5 mg ORAL ANDA 12 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 42291-729 TABLET 10 mg ORAL ANDA 12 sections
Prochlorperazine maleate HUMAN PRESCRIPTION DRUG LABEL 1 42708-103 TABLET 10 mg ORAL ANDA 12 sections
Prochlorperazine Maleate HUMAN PRESCRIPTION DRUG LABEL 1 43063-353 TABLET, FILM COATED 5 mg ORAL ANDA 14 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 43063-742 TABLET 10 mg ORAL ANDA 12 sections
PROCHLORPERAZINE MALEATE HUMAN PRESCRIPTION DRUG LABEL 1 43063-742 TABLET 10 mg ORAL ANDA 12 sections